The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Placebo Outperforms Glucosamine/Chondroitin Sulfate for Knee OA

Placebo Outperforms Glucosamine/Chondroitin Sulfate for Knee OA

August 24, 2016 • By Erin Blakemore

  • Tweet
  • Email
Print-Friendly Version / Save PDF

(Reuters Health)—Glucosamine sulfate and chondroitin sulfate are not more beneficial than placebo treatments for patients with knee osteoarthritis, a recent trial suggests.

You Might Also Like
  • Does Chondroitin Trump Celecoxib for Arthritic Knee Pain?
  • Glucosamine Supplements Don’t Help Knee or Hip Arthritis Pain
  • New Research Shows Chondroitin Sulphate Reduces Cartilage Volume Loss, Bone Marrow Lesions

In a double-blind study, researchers investigated the efficacy of a medicine that delivered both glucosamine and chondroitin sulfate. The 164 participants all had osteoarthritis and moderate to severe knee pain.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Half the participants were randomly assigned to receive the experimental drug (1,200 mg chondroitin sulfate plus 1,500 mg glucosamine sulfate) and the other half received a placebo. Each participant reported their global pain levels and used a questionnaire to report on osteoarthritis-related pain.

The study was intended to consist of two steps: a six-month initial phase and a second phase that would be initiated if initial patient response was strong. Unexpectedly, the results were so strongly skewed toward the placebo that the study was discontinued.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“Intriguingly,” the authors report, the combination pill was inferior to placebo in reduction of joint pain on a visual analog scale for the modified intention-to-treat population (19% vs. 33%; P<0.03), but there was no difference between groups in the per-protocol cohort. Among patients who completed the entire six-month trial, 13.6% who took the drug reported reduced pain levels compared to 20.1% of those who took the placebo (P=0.07).

Nor were there any differences in secondary outcomes (i.e., total score on WOMAC [Western Ontario and McMaster Universities Arthritis Index]), and pain and function subscales, the proportion of OMERACT-OARSI (Outcome Measures in Rheumatology-Osteoarthritis Research Society International) responders, and use of rescue medication.

The study is the latest in a line of clinical trials that show little to no benefit for glucosamine or chondroitin in the treatment of osteoarthritis or knee pain.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Jorge Roman-Blas of Madrid’s Fundacion Jimenez Diaz Hospital, the study’s first author, tells Reuters Health via email that adverse effects, such as diarrhea and abdominal pain, were more common in those who took the glucosamine-chondroitin sulfate drug.

He acknowledged that the small sample size and the fact that patients were allowed to occasionally use acetaminophen as a rescue drug could have influenced the outcome.

“Maybe more strict statistical criteria could be required for (future) clinical trials based on health questionnaires,” he adds.

The study was published July 31 in Arthritis and Rheumatology.

“This study adds to a growing body of literature which (has) failed to demonstrate that these supplements offer relief from osteoarthritis,” Kate Lapane of the University of Massachusetts Medical School tells Reuters Health via email.

Pages: 1 2 | Single Page

Filed Under: Conditions, Drug Updates, Osteoarthritis Tagged With: Arthritis & Rheumatology, chondroitin sulfate, glucosamine sulfate, knee, Knee Osteoarthritis (OA), knee pain, placebo

You Might Also Like:
  • Does Chondroitin Trump Celecoxib for Arthritic Knee Pain?
  • Glucosamine Supplements Don’t Help Knee or Hip Arthritis Pain
  • New Research Shows Chondroitin Sulphate Reduces Cartilage Volume Loss, Bone Marrow Lesions
  • Effectiveness of Steroid Injections vs. Placebo Evaluated for Knee Pain

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.